Characterizing the cutaneous late effects of allogeneic hematopoietic stem cell transplantation: A systematic review

被引:0
|
作者
Bourkas, Adrienn N. [1 ,2 ]
Sibbald, Cathryn [2 ,3 ]
Chan, An-Wen [3 ]
Schechter, Tal [4 ]
Ali, Muhammad [4 ]
Pullattayil, Abdul Kareem [5 ]
Levy, Rebecca [2 ,6 ]
机构
[1] Queens Univ, Dept Med, Kingston, ON, Canada
[2] Univ Toronto, Hosp Sick Children, Div Dermatol, Toronto, ON, Canada
[3] Univ Toronto, Dept Med, Div Dermatol, Toronto, ON, Canada
[4] Univ Toronto, Hosp Sick Children, Div Haematol Oncol BMT, Toronto, ON, Canada
[5] Queens Univ, Bracken Hlth Sci Lib, Kingston, ON, Canada
[6] Hosp Sick Children, Div Dermatol, 555 Univ Ave, Toronto, ON M5G 1X8, Canada
关键词
carcinoma; basal cell; squamous cell; hematopoietic stem cell transplantation; melanoma; skin neoplasms; NONMELANOMA SKIN-CANCER; VERSUS-HOST-DISEASE; MALIGNANT NEOPLASMS; SOLID CANCERS; CHILDHOOD; RISK; IRRADIATION; LEUKEMIA; CHILDREN; IMPACT;
D O I
10.1111/petr.14618
中图分类号
R72 [儿科学];
学科分类号
100202 ;
摘要
BackgroundThere is a well-documented risk of secondary cutaneous malignancies following allogeneic hematopoietic stem cell transplant (HSCT), but data on risk in pediatric populations are limited. The objective of this study is to perform a systematic review of reported features and outcomes of skin cancers in pediatric allogeneic HSCT recipients.MethodsMEDLINE, EMBASE, CINAHL, Cochrane, and Web of Science were systematically searched (Prospero CRD42022342139). Studies reporting cutaneous cancer outcomes were included if the age at transplant was <= 19 years. Titles, abstracts, and full-text articles were screened in duplicate.ResultsOut of 824 citations that were screened, 12 articles were selected for analysis. The final sample included 67 pediatric HSCT recipients, comprising 65 allogeneic transplant recipients and 2 cases of HSCT with an unknown donor type. The median age at transplant and skin cancer diagnosis were 7.4 and 13 years, respectively. Out of the 67 pediatric HSCT recipients, some patients developed more than one lesion, resulting in 71 lesions. The most common skin cancer type was cutaneous squamous cell carcinoma (32 lesions), followed by basal cell carcinoma (25 lesions). The median latency period between HSCT and skin cancer diagnosis ranged from 0 to 29 years. Identified risk factors for skin cancers included younger age at the time of transplant, exposure to total body irradiation, prolonged post-transplant immunosuppression, graft versus host disease, and sunburn.ConclusionSkin cancers are reported in pediatric allogeneic HSCT recipients, and the risk appears to be increased. More data are needed to better characterize this risk. This systematic review highlights elevated cutaneous malignancy risks in pediatric patients after allogeneic HSCT, emphasizing the need for long-term monitoring. The findings underscore the significance of enhanced surveillance and preventive measures to mitigate these risks.image
引用
收藏
页数:9
相关论文
共 50 条
  • [41] Nonablative allogeneic hematopoietic stem cell transplantation
    Dansey, RD
    Baynes, RD
    CURRENT OPINION IN ONCOLOGY, 2001, 13 (01) : 27 - 32
  • [42] Allogeneic hematopoietic stem cell transplantation in Tunisia
    Ben Othman, T.
    Torjemane, L.
    Abdelkefi, A.
    Lakhal, A.
    Ladeb, S.
    Ben Hamed, L.
    Slama, H.
    Ben Abdeladhim, A.
    BONE MARROW TRANSPLANTATION, 2008, 42 (Suppl 1) : S139 - S141
  • [43] Allogeneic hematopoietic stem cell transplantation in the elderly
    Shapira, Michael Y.
    Tsirigotis, P.
    Resnick, I. B.
    Or, R.
    Abdul-Hai, A.
    Slavin, S.
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2007, 64 (01) : 49 - 63
  • [44] Immunobiology of allogeneic hematopoietic stem cell transplantation
    Welniak, Lisbeth A.
    Blazar, Bruce R.
    Murphy, William J.
    ANNUAL REVIEW OF IMMUNOLOGY, 2007, 25 : 139 - 170
  • [45] Costs of allogeneic hematopoietic stem cell transplantation
    Svahn, Britt-Marie
    Alvin, Ole
    Ringden, Olle
    Gardulf, Ann
    Remberger, Mats
    TRANSPLANTATION, 2006, 82 (02) : 147 - 153
  • [46] Costs of allogeneic hematopoietic stem cell transplantation
    Svahn, BMBMS
    Alvin, OOA
    Ringden, OOR
    Gardulf, AAG
    Remberger, MMR
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2006, 12 (02) : 25 - 25
  • [47] Allogeneic hematopoietic stem cell transplantation for myelofibrosis
    Deeg, HJ
    Gooley, TA
    Flowers, MED
    Sale, GE
    Slattery, JT
    Anasetti, C
    Chauncey, TR
    Doney, K
    Georges, GE
    Kiem, HP
    Martin, PJ
    Petersdorf, EW
    Radich, J
    Sanders, JE
    Sandmaier, BM
    Warren, EH
    Witherspoon, RP
    Storb, R
    Appelbaum, FR
    BLOOD, 2003, 102 (12) : 3912 - 3918
  • [48] Allogeneic hematopoietic stem cell transplantation for myelofibrosis
    Barosi, Giovanni
    Bacigalupo, Andrea
    CURRENT OPINION IN HEMATOLOGY, 2006, 13 (02) : 74 - 78
  • [49] Nonmyeloablative allogeneic hematopoietic stem cell transplantation
    Baron, F
    Beguin, Y
    JOURNAL OF HEMATOTHERAPY & STEM CELL RESEARCH, 2002, 11 (02): : 243 - 263
  • [50] Allogeneic hematopoietic stem cell transplantation for lymphoma
    Dean, RM
    Bishop, MR
    CLINICAL LYMPHOMA, 2004, 4 (04): : 238 - 249